Polivy 30mg, 140mg (IV) Polatuzumab vedotin
Intended for healthcare professionals only
This material should not be used as a substitute for professional medical advice or to promote any medication. For more information, please consult your physician
Polatuzumab vedotin is a CD79b-targeted antibody-drug conjugate that preferentially delivers a potent anti-mitotic agent (monomethyl auristatin E, or MMAE) to B-cells, which results in the killing of malignant B-cells. Polivy is approved for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma, and adult patients with relapsed/refractory diffuse large B-cell lymphoma who are not candidates for haematopoietic stem cell transplant.
Full prescribing information is available on request.
If you have a scientific query related to one of Roche's products, please contact us at [email protected]
In case of any adverse events or safety queries, please contact [email protected]
M-PK-00001707
Solutions
Pharma Products
![[Product] Polivy](https://assets.roche.com/f/169232/1600x1065/e13893acec/polivy-140mg.png/m/320x180/filters:format(webp):quality(90)/)